2. UroToday Home
  3. Conference Highlights
  4. ASCO 2017
  5. ASCO 2017 Renal Cancer

ASCO 2017

ASCO 2017: Long-term response and time to response to pazopanib and sunitinib in metastatic renal cell carcinoma: COMPARZ subanalysis

Chicago, IL (UroToday.com) COMPARZ (NCT00720941) was a phase 3, randomized, controlled, open-label trial that demonstrated comparable efficacy of first-line pazopanib (PAZ) and sunitinib (SUN), but favorable safety and quality of life profiles for PAZ in 1110 patients with mRCC.1 The objectives of this study were to identify patients from COMPARZ who exhibited a long-term response to PAZ and SUN, determine time to response, and describe the clinical characteristics of patients who achieved LTR.

Patients in the intention-to-treat population of COMPARZ were analyzed for differences in long term response (≥10 months) as measured by responder rate with either complete response or partial response (CR/PR) and progression free survival (PFS) rate, and time to response. The authors also compared the clinical characteristics between long-term and shorter-term responders within and between each treatment arm.

The overall percentage of long-term responders with CR/PR (PAZ = 14%, SUN = 13%) and PFS (PAZ = 31.4%, SUN = 33.6%) in the PAZ and SUN groups were similar. This similarity was observed regardless of the cut-off for long-term duration of response. However, a shorter time to achieve CR/PR was observed in the overall population with PAZ (11.9 weeks [95% CI, 11.3–12.1] vs 17.4 weeks; [95% CI, 12.7–18.0]).

These exploratory sub-analyses in long-term responders support the overall efficacy results with PAZ and SUN, which were reported in the COMPARZ trial.1 However, the results here demonstrated that the time to response was shorter with PAZ compared to SUN.

Presented By: Nizar M. Tannir, The University of Texas MD Anderson Cancer Center, Houston, TX

Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre
Twitter: @GoldbergHanan

at the 2017 ASCO Annual Meeting - June 2 - 6, 2017 – Chicago, Illinois, USA

Reference:
Casper J, Schumann-Binarsch S, Kohne CH. Pazopanib versus sunitinib in renal cancer. The New England journal of medicine 2013; 369(20): 1969.